ME03682B - Isporuka holesteril estra u steroidogeno tkivo - Google Patents
Isporuka holesteril estra u steroidogeno tkivoInfo
- Publication number
- ME03682B ME03682B MEP-2020-1A MEP120A ME03682B ME 03682 B ME03682 B ME 03682B ME P120 A MEP120 A ME P120A ME 03682 B ME03682 B ME 03682B
- Authority
- ME
- Montenegro
- Prior art keywords
- lcat
- use according
- condition
- phospholipids
- complex
- Prior art date
Links
- 230000000365 steroidogenetic effect Effects 0.000 title claims 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 150000003431 steroids Chemical class 0.000 claims 5
- -1 cholesteryl ester Chemical class 0.000 claims 4
- 150000003904 phospholipids Chemical class 0.000 claims 4
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 102000007592 Apolipoproteins Human genes 0.000 claims 2
- 108010071619 Apolipoproteins Proteins 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 claims 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000003163 gonadal steroid hormone Substances 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 201000011200 hepatorenal syndrome Diseases 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 231100001229 severe poisoning Toxicity 0.000 claims 1
- 230000010009 steroidogenesis Effects 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (10)
1. Lecitin: holesterol aciltransferaza (LCAT) za upotrebu pri tretiranju pacijenta koji ima stanje gde je smanjena funkcija steroidogenog tkiva, gde je stanje akutno stanje koje je izabrano iz grupe koju čine infekcija, sepsa, povreda, opekotine, bolest jetre, transplantacijaorgana ili trovanje teškim metalom.
2. LCAT za upotrebu pri povećanoj steroidogenezi steroida kod pacijenta koji boluje od stanja gde je smanjena funkcija steroidogenog tkiva, gde je navedeno stanje akutno stanje koje je izabrano iz grupe koju čine infekcija, sepsa, povreda, opekotine, bolest jetre, transplantacijaorgana ili trovanje teškim metalom.
3. LCAT za upotrebu prema patentnom zahtevu 2, gde je steroid kortikosteroid ili polni hormon.
4. LCAT za upotrebu prema patentnom zahtevu 3, gde je steroid kortizol, aldosteron, testosteron ili estrogen.
5. LCAT za upotrebu prema bilo kom od patentnih zahteva 1-4, u kombinaciji sa česticom za isporuku holesterola (CDP).
6. LCAT za upotrebu prema patentnom zahtevu 5, gde je COP nativni HDL, rekonstituisaniHDL ili HOL mimetik, gdenativni HOL predstavlja HDL izolovan iz plazme;rekonstituisani HDL predstavlja kompleks apolipoproteina Al, fosfolipida i holesteril estra; ili kompleks apolipoproteina Al, fosfolipida, holesterola i holesteril estra; iHDL mimetik predstavlja kompleks od jednog ili više alifatnih peptida 18-40 amino kiselina u dužini, fosfolipida i holesteril estra; ili kompleks od jednog ili više alifatnih peptida 18-40 amino kiselina u dužini, fosfolipida, holesterola i holesteril estra.
7. LCAT za upotrebu prema patentnom zahtevu 5 ili patentnom zahtevu 6, gde se CDP daje kao bolus doza pre davanja LCAT.
8. LCAT za upotrebu prema bilo kom od patentnih zahteva 2-4, gde su nivoi steroida povećani do normalnog nivoa.•
9. LCAT za upotrebu prema bilo kom od patentnih zahteva 2-4, gde su nivoi steroidapovećani preko normalnog nivoa.
10.LCAT za upotrebu prema bilo kom od patentnih zahteva 1-6, gde je stanje bolest jetre koje je izabrano iz grupe koju čine hepatitis, hepatorenalni sindrom, fibroza, ciroza, hiperplazija žučnih vodova ili atrezija žučnih vodova.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33190910P | 2010-05-06 | 2010-05-06 | |
| EP11720265.5A EP2566505B1 (en) | 2010-05-06 | 2011-05-06 | Delivery of cholesteryl ester to steroidogenic tissues |
| PCT/US2011/035500 WO2011140429A1 (en) | 2010-05-06 | 2011-05-06 | Delivery of cholesteryl ester to steroidogenic tissues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03682B true ME03682B (me) | 2021-01-20 |
Family
ID=44121177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2020-1A ME03682B (me) | 2010-05-06 | 2011-05-06 | Isporuka holesteril estra u steroidogeno tkivo |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20130045194A1 (me) |
| EP (1) | EP2566505B1 (me) |
| JP (1) | JP6174995B2 (me) |
| CN (1) | CN103025348B (me) |
| AU (1) | AU2011247985B2 (me) |
| BR (1) | BR112012028462A2 (me) |
| CA (1) | CA2797126C (me) |
| CY (1) | CY1122827T1 (me) |
| DK (1) | DK2566505T3 (me) |
| ES (1) | ES2764733T3 (me) |
| HR (1) | HRP20200008T1 (me) |
| HU (1) | HUE047288T2 (me) |
| LT (1) | LT2566505T (me) |
| ME (1) | ME03682B (me) |
| MX (1) | MX336872B (me) |
| NZ (1) | NZ603453A (me) |
| PL (1) | PL2566505T3 (me) |
| PT (1) | PT2566505T (me) |
| RS (1) | RS59867B1 (me) |
| RU (1) | RU2012152320A (me) |
| SI (1) | SI2566505T1 (me) |
| SM (1) | SMT202000011T1 (me) |
| WO (1) | WO2011140429A1 (me) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2853259A1 (en) * | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| JP2021501793A (ja) * | 2017-11-07 | 2021-01-21 | アルファコア ファーマ リミテッド ライアビリティ カンパニーＡｌｐｈａｃｏｒｅ Ｐｈａｒｍａ Ｌｌｃ | 心疾患、心血管疾患及び関連する病状と症状を治療し保護する方法 |
| EP4259280A4 (en) * | 2020-12-11 | 2025-02-12 | The Regents Of The University Of Michigan | Compositions and methods for preventing, attenuating, and treating medical conditions with shdl nanoparticles |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2259179C (en) * | 1996-07-03 | 2008-09-23 | University Of Pittsburgh | Emulsion formulations for hydrophilic active agents |
| US6498019B1 (en) * | 1997-04-11 | 2002-12-24 | Takeda Chemical Industries, Ltd. | Lecithin-cholesterol acyltransferase protein |
| WO2003009704A2 (en) * | 2001-07-27 | 2003-02-06 | N.V. Nutricia | Enteral compositions for the prevention and/or treatment of sepsis |
| IL158554A0 (en) * | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Mimetic lipids as dietary supplements |
| JP2007530550A (ja) | 2004-03-26 | 2007-11-01 | イーライ リリー アンド カンパニー | 異脂肪血症を治療するための化合物および方法 |
| US20080096900A1 (en) | 2006-06-26 | 2008-04-24 | Amgen Inc. | Methods for treating atherosclerosis |
| HRP20140315T1 (hr) * | 2007-07-26 | 2014-05-09 | Amgen Inc. | Modificirani enzimi lecitin-kolesterol aciltransferaze |
| WO2009124055A1 (en) * | 2008-03-31 | 2009-10-08 | University Of Chicago | Human apoa-i mutants |
| JP5759988B2 (ja) * | 2009-06-12 | 2015-08-05 | アルファコア ファーマ リミテッド ライアビリティ カンパニーＡｌｐｈａｃｏｒｅ Ｐｈａｒｍａ Ｌｌｃ | 貧血および赤血球機能不全を治療するためのｌｃａｔの使用 |
-
2011
- 2011-05-06 CN CN201180022792.7A patent/CN103025348B/zh not_active Expired - Fee Related
- 2011-05-06 RS RS20200004A patent/RS59867B1/sr unknown
- 2011-05-06 ME MEP-2020-1A patent/ME03682B/me unknown
- 2011-05-06 EP EP11720265.5A patent/EP2566505B1/en active Active
- 2011-05-06 ES ES11720265T patent/ES2764733T3/es active Active
- 2011-05-06 AU AU2011247985A patent/AU2011247985B2/en not_active Ceased
- 2011-05-06 SI SI201131832T patent/SI2566505T1/sl unknown
- 2011-05-06 MX MX2012012711A patent/MX336872B/es active IP Right Grant
- 2011-05-06 LT LTEP11720265.5T patent/LT2566505T/lt unknown
- 2011-05-06 HU HUE11720265A patent/HUE047288T2/hu unknown
- 2011-05-06 PT PT117202655T patent/PT2566505T/pt unknown
- 2011-05-06 NZ NZ603453A patent/NZ603453A/en not_active IP Right Cessation
- 2011-05-06 HR HRP20200008TT patent/HRP20200008T1/hr unknown
- 2011-05-06 WO PCT/US2011/035500 patent/WO2011140429A1/en not_active Ceased
- 2011-05-06 US US13/695,919 patent/US20130045194A1/en not_active Abandoned
- 2011-05-06 DK DK11720265.5T patent/DK2566505T3/da active
- 2011-05-06 RU RU2012152320/15A patent/RU2012152320A/ru not_active Application Discontinuation
- 2011-05-06 PL PL11720265T patent/PL2566505T3/pl unknown
- 2011-05-06 CA CA2797126A patent/CA2797126C/en not_active Expired - Fee Related
- 2011-05-06 SM SM20200011T patent/SMT202000011T1/it unknown
- 2011-05-06 JP JP2013509288A patent/JP6174995B2/ja not_active Expired - Fee Related
- 2011-05-06 BR BR112012028462A patent/BR112012028462A2/pt not_active IP Right Cessation
-
2014
- 2014-09-05 US US14/478,456 patent/US20150190479A1/en not_active Abandoned
-
2020
- 2020-01-09 CY CY20201100021T patent/CY1122827T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012152320A (ru) | 2014-06-20 |
| ES2764733T3 (es) | 2020-06-04 |
| SMT202000011T1 (it) | 2020-03-13 |
| PL2566505T3 (pl) | 2020-06-29 |
| MX2012012711A (es) | 2012-11-21 |
| HUE047288T2 (hu) | 2020-04-28 |
| AU2011247985B2 (en) | 2015-12-03 |
| MX336872B (es) | 2016-02-04 |
| RS59867B1 (sr) | 2020-03-31 |
| BR112012028462A2 (pt) | 2016-07-19 |
| EP2566505B1 (en) | 2019-10-16 |
| HRP20200008T1 (hr) | 2020-03-20 |
| LT2566505T (lt) | 2020-02-10 |
| EP2566505A1 (en) | 2013-03-13 |
| WO2011140429A1 (en) | 2011-11-10 |
| CN103025348B (zh) | 2015-09-02 |
| DK2566505T3 (da) | 2020-01-20 |
| CY1122827T1 (el) | 2021-05-05 |
| AU2011247985A1 (en) | 2012-11-29 |
| US20150190479A1 (en) | 2015-07-09 |
| CN103025348A (zh) | 2013-04-03 |
| CA2797126A1 (en) | 2011-11-10 |
| US20130045194A1 (en) | 2013-02-21 |
| JP2013528594A (ja) | 2013-07-11 |
| NZ603453A (en) | 2014-12-24 |
| CA2797126C (en) | 2020-06-02 |
| PT2566505T (pt) | 2020-01-15 |
| JP6174995B2 (ja) | 2017-08-02 |
| SI2566505T1 (sl) | 2020-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Slijepcevic et al. | Na+‐taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice | |
| Bertolini et al. | Bile acids and their receptors: modulators and therapeutic targets in liver inflammation | |
| Evangelakos et al. | Role of bile acids in inflammatory liver diseases | |
| McConnell et al. | The evolving role of liver sinusoidal endothelial cells in liver health and disease | |
| Xu et al. | Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism | |
| De Cassan et al. | Second-generation corticosteroids for the treatment of Crohn’s disease and ulcerative colitis: more effective and less side effects? | |
| Ma et al. | Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice | |
| Oliveira et al. | N-acetylcysteine and/or ursodeoxycholic acid associated with metformin in non-alcoholic steatohepatitis: an open-label multicenter randomized controlled trial | |
| Wang et al. | Hepatoprotective effect of phillygenin on carbon tetrachloride-induced liver fibrosis and its effects on short chain fatty acid and bile acid metabolism | |
| Tang et al. | A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development | |
| ME03682B (me) | Isporuka holesteril estra u steroidogeno tkivo | |
| Yu et al. | The PI3K/Akt pathway mediates the nongenomic cardioprotective effects of estrogen following trauma-hemorrhage | |
| Jiang et al. | Protective effect of aescin from the seeds of Aesculus hippocastanum on liver injury induced by endotoxin in mice | |
| Corpechot | Primary biliary cirrhosis and bile acids | |
| Li et al. | Exogenous S-nitrosoglutathione attenuates inflammatory response and intestinal epithelial barrier injury in endotoxemic rats | |
| Li et al. | Modification effects of SanWei GanJiang Powder on liver and intestinal damage through reversing bile acid homeostasis | |
| Xu et al. | Ulinastatin suppresses systemic inflammatory response following lung ischemia-reperfusion injury in rats | |
| Cazzagon et al. | Protective potential of the gallbladder in primary sclerosing cholangitis | |
| VANGE et al. | Effects of seven low dose combined oral contraceptives on high density lipoprotein subfractions | |
| Beuers et al. | Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-) transcriptional modulators? | |
| TW202038911A (zh) | 環孢素類似物之藥學調合物 | |
| Cai et al. | The Role of Bile Acid‐Mediated Inflammation in Cholestatic Liver Injury | |
| Bartko et al. | Dexamethasone inhibits endotoxin‐induced coagulopathy in human lungs | |
| Ba et al. | Testosterone receptor blockade after trauma and hemorrhage attenuates depressed adrenal function | |
| Herraez et al. | Protective effect of bile acid derivatives in phalloidin-induced rat liver toxicity |